Selumetinib compared with carboplatin and vincristine for low-grade glioma
Original title: A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a large, late stage study comparing a new drug with the usual treatment.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study compares a pill called selumetinib with the usual chemotherapy for a slow-growing brain tumor.
Who this trial is for. This study is for people with a low-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary that was just found, or that has not been treated yet. It is for tumors that do not have a gene change called BRAFV600E, and that are not linked to neurofibromatosis type 1. Half the study tests selumetinib. The other half tests the usual treatment, carboplatin and vincristine.
Where it stands. There are no results to share. The study is still going. It is measuring whether selumetinib works as well as the usual treatment, which of the two works better, and whether selumetinib makes daily life better for the people who take it. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: This is one more option being looked at for this kind of tumor. If this sounds like your situation, you can ask your care team about it. They can tell you if a study like this makes sense for you.
What it doesn't mean: This does not mean selumetinib is proven. A trial is a test, not a treatment your doctor can simply give you. Joining a trial does not mean you will be helped by it. And this is not a promise of a cure.
Source: ClinicalTrials.gov, August 4, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.